Cited by

• Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

  Singh P, Wesley C, Jadaun GP, Malonia SK, Das R, Upadhyay P, Faujdar J, Sharma P, Gupta P, Mishra AK, Singh K, Chauhan DS, Sharma VD, Gupta UD, Venkatesan K, Katoch VM. Singh P, et al. J Clin Microbiol. 2007 Jan;45(1):76-80. doi: 10.1128/JCM.00951-06. Epub 2006 Nov 8. J Clin Microbiol. 2007. PMID: 17093022 Free PMC article.
• Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

  Butler WR, Kilburn JO. Butler WR, et al. J Clin Microbiol. 1982 Dec;16(6):1106-9. doi: 10.1128/jcm.16.6.1106-1109.1982. J Clin Microbiol. 1982. PMID: 6819309 Free PMC article.
• Activity of Pyrazinamide against Mycobacterium tuberculosis at Neutral pH in PZA-S1 Minimal Medium.

  Shi W. Shi W. Antibiotics (Basel). 2021 Jul 26;10(8):909. doi: 10.3390/antibiotics10080909. Antibiotics (Basel). 2021. PMID: 34438959 Free PMC article.
• Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis.

  Rastogi N, Potar MC, David HL. Rastogi N, et al. Antimicrob Agents Chemother. 1988 Feb;32(2):287. doi: 10.1128/AAC.32.2.287. Antimicrob Agents Chemother. 1988. PMID: 3129990 Free PMC article. No abstract available.
• A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites.

  Ramachandran A, Gadgil CJ. Ramachandran A, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1274-1284. doi: 10.1002/psp4.13008. Epub 2023 Jul 16. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37431175 Free PMC article.